Пошук Зображення Карти YouTube Новини Gmail Диск Календар Більше »
Увійти
Для користувачів програм зчитування з екрана: натисніть це посилання, щоб перейти в режим доступності. Режим доступності має всі основні функції, але краще працює з програмою зчитування з екрана.

Патенти

  1. Розширений пошук патентів
Номер публікаціїUSRE33093 E
Тип публікаціїВиданий патент
Номер заявкиUS 07/272,354
Дата публікації17 жов. 1989
Дата реєстрації заявки16 лис. 1988
Дата пріоритету16 чер. 1986
Статус патентного зборуСплачено
Номер публікації07272354, 272354, US RE33093 E, US RE33093E, US-E-RE33093, USRE33093 E, USRE33093E
ВинахідникиMichael T. Schiraldi, Martin M. Perl, Howard Rubin
Оригінальний правонаступникJohnson & Johnson Consumer Products, Inc.
Експортувати цитуванняBiBTeX, EndNote, RefMan
Зовнішні посилання: USPTO (Бюро патентів і товарних знаків США), USPTO – передача прав, Espacenet
Bioadhesive extruded film for intra-oral drug delivery and process
US RE33093 E
Анотація
A bioadhesive extruded single or multi-layered thin film, especially useful in intra-oral controlled-releasing delivery, having a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.]. .Iadd.20-92.Iaddend.% by weight of a hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer such as ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a medicament, e.g. anesthetics, analgesics, anticaries agents, anti-inflammatories, antihistamines, antibiotics, antibacterials, fungistats, etc.
Зображення(7)
Previous page
Next page
Патентна формула(9)
What is claimed is:
1. A pharmaceutically acceptable controlled-releasing medicament-containing extruded single or multi-layered thin film, capable of adhering to a wet mucous surface, comprising a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.]..Iadd.20-93.Iaddend.% by weight of a hydroxypropyl cellulose having a molecular weight above 100,000, 5-60% of a homopolymer of ethylene oxide having a molecular weight from 3,000,000 to 5,000,000, 0-10% of a water-insoluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a pharmaceutically effective amount of said medicament.
2. The extruded film of claim 1, made in a form which is so thin and flexible when wet as to be unobtrusive to the patient when properly positioned and placed in the patients mouth.
3. The extruded film of claim 2 having a thickness no greater than 0.25 millimeters.
4. The extruded film of claim 1, in single layer form, which also contains up to 10% by weight of a non-soluble polymer selected from the group consisting of ethyl cellulose, polyethylene, polypropylene and carboxymethyl cellulose free acid.
5. The extruded film of claim 1, in multi-layer laminated form, which is addition to the bioadhesive layer also contains a reservoir layer in which at least a major portion of the medicament is contained.
6. The extruded multi-layer film of claim 5 in which the reservoir layer consists essentially of a polymer matrix comprised of both a water soluble or swellable polymer and a non-water soluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and also hydroxypropyl cellulose.
7. The extruded film of claim 1 in multi-layer laminated form, which in addition to the bioadhesive layer also contains an outer protective-barrier membrane layer.
8. The extruded multi-layer film of claim 7 in which the outer protective-barrier membrane layer is thinner than the bioadhesive layer, and said outer protective barrier layer consists essentially of a polymer matrix of a major proportion of a non-water-soluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and a minor proportion of hydroxypropyl cellulose.
9. The extruded multi-layer film of claim 1 in the form of a triple layered laminate containing sodium fluoride for anticaries protection having the following composition:
______________________________________                              Outer                              Protective           Bio-     % w/w     Barrier           adhesive Reservoir Membrane           Layer    Layer     LayerIngredients     (0.1 mm) (0.025 mm)                              (0.025 mm)______________________________________Polyethylene oxide           60.0     --        --homopolymer(MW 3,000,000 minimum)Hydroxypropyl Cellulose           30.0     20.0      24.0(MW 1,000,000)Polyethylene (Low Density)           5.0      --        --Propylene Glycol U.S.P.           3.0      --        --Polyethylene Glycol           2.0      --        --(MW 400)Ethyl Cellulose --       59.0      69.6Caprylic/Capric --        5.0      6.0TriglycerideSodium Flouride --       16.0      0.4           100.0    100.0     100.0______________________________________
Опис
BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a controlled-releasing medicament-containing preparation for intra-oral use, and is more especially concerned with such a preparation (and the process of using it) in the form of a very thin extruded thermoplastic film (which can be in single layer or laminated multi-layer form) having at least one bioadhesive layer containing .[.40-95.]..Iadd.20-93.Iaddend.% of a thermoplastic cellulose ether and 5-60% of a homopolymer of ethylene oxide which can adhere to the mucosa of the oral cavity. The extruded film drug delivery system of the present invention, which has incorporated therein the medicament to be dispensed, is so thin and flexible when wet as to be unobtrusive to the patient after it has been properly positioned and placed in the mouth.

2. Description of the Prior Art

Several systems have previously been described which pertain to the delivery of drugs into the oral cavity. These include:

1. Treatment of periodontal disease with tetracycline, chlorhexidine or metronidazole loaded into hollow cellulose acetate fibers. These fibers are packed in the periodontal pockets and provide controlled release of the drug to the infected area.

2. Cast films containing ethyl cellulose/propylene glycol with chlorhexidine or metronidazole for treatment of periodontal disease.

3. An orthodontic appliance with a hydroxyethyl methacrylate/methyl methacrylate copolymer (HEMA/MMA) matrix. Sodium fluoride is incorporated into the HEMA/MMA matrix to provide sustained fluoride release and enhanced anticaries activity. HEMA/MMA with fluoride may also be attached to the tooth in the form of a wafer-like tablet.

4. Silicone/ethyl cellulose/polyethylene glycol films containing sodium fluoride are applied as coatings on orthodontic bands or in chewing gum. Controlled release of fluoride and anticaries activity is claimed. The above systems are discussed in the "The Compendium of Continuing Education" Vol VI, No. 1, January 1985 p. 27-36 review article "Controlled Drug Delivery: A New Means of Treatment of Dental Disease", by J. Max Goodson, D.D.S., Ph.D. of the Forsyth Dental Center. Other systems, described in GB patent application No. 2,042,888 and U.S. Pat. Nos. 4,292,299/4,226,848 (Teijin Ltd., Japan), use combinations of cellulosic and polyacrylate polymers. The preferred materials are hydroxypropyl cellulose ("Klucel") and a copolymer of acrylic acid ("Carbopol") that is administered in the form of thin tablets (discs), granules or powder. Other polymers that might be added are vinyl copolymers, polysaccharides, gelatin and collagen. U.S. Pat. No. 4,517,173 (Nippon Soda Co. Ltd, Japan) uses various celluloses in a multi-layered non-extruded cast film preparation.

Examples of prior art products currently on the market include ointments such as ORABASE* with Benzocaine (Squibb), Kenalog* (Triamcinolone Acetonide) in ORABASE* (Squibb) and Mycostatin* (Nystatin) ointment (Squibb).

The prior art products and delivery systems described above are useful but have the following disadvantages:

Tablets, appliances, hollow fibers are "bulky" in the mouth, are difficult to keep in place and inconvenient to apply.

Ethyl cellulose and/or silicone films do not adhere to mucosal tissue.

Ointments (i.e., ORABASE*) have an unpleasant feel and do not last very long.

Except for ORABASE*, all the foregoing systems require professional application to the tooth or periodontal pockets.

The bioadhesive film of the present invention alleviates many of the above problems. It may be applied easily by the consumer. It has very little or no mouthfeel, it has good adhesion to the mucosal tissues, and provides controlled release of the medicament.

OBJECT OF THE INVENTION

It is an object of this invention to provide an extruded film that is an effective and convenient intra-oral drug delivery system and method for applying and delivering controlled dosages of therapeutic agents into the oral cavity. This technology may also be extended for controlled drug delivery in skin care, gynecological applications, wound care and like uses.

SUMMARY OF THE INVENTION

The invention involves a pharmaceutically acceptable controlled-releasing medicament-containing extruded single or multi-layered thin film, capable of adhering to a wet mucous surface, comprising a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.Iadd.20-93.Iaddend.% by weight of hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a pharmaceutically effective amount of said medicament.

The present invention is directed to an extruded single or multi-layered laminated thin (1-10 mils or 0.025-0.25 mm) film, composed of selected water soluble and/or insoluble polymers. Various therapeutic agents are incorporated into the film during manufacture which are useful for treatment of oral disorders (i.e., denture discomfort, caries, periodontal disease, aphthous ulcers, etc.).

The extruded film of the present invention must have at least one bioadhesive layer, but may also have a reservoir layer and/or an outer protective barrier membrane layer. The therapeutic agent may be incorporated into any or all of the layers. When properly formulated and fabricated, these films will adhere to wet mucosal surfaces, provide a protective barrier for injured tissue and deliver controlled/sustained dosages of medication to the infected areas. The film may be designed for localized drug delivery (i.e., the periodontal pocket, an aphthous lesion), or may allow diffusion of the drug into the oral cavity.

An example of a non-localized system would be the delivery of sodium fluoride for caries prevention. A single or laminated film with good adhesion to the tooth or mucosal tissue may be employed in which the fluoride release rates may be controlled by varying film solubilities and/or concentration of fluoride in a multi-layered film.

An example of a localized application of medication would be in the treatment of aphthous lesions. A laminated two layer film with benzocaine incorporated into the adhesive layer would directly contact the injured mucosa. The outer layer would consist of non-soluble/non-adhesive polymers that provide durability, protection and directs the delivery of benzocaine toward the lesion.

The film forming polymers that are useful in this invention are selected from pharmaceutical grade materials, or those that are considered generally regarded as safe (GRAS) as food additives. They include, hydroxypropyl cellulose, and polyethylene oxide homopolymers. Small amounts of other polymers, e.g., polyvinyl ether-maleic acid copolymers and the like may be used in small amounts as well, replacing a small portion of the other polymers. The above materials are either water soluble of swellable and are most useful in the bioadhesive layer of the film. Various non-soluble polymers may also be incorporated for modification of the film's permeability properties, such as ethyl cellulose, propyl cellulose, polyethylene, polypropylene and carboxymethylcellulose (free acid). By varying the ratios of the above polymers both the solubility and the adhesive properties of each layer of film may be controlled. Therefore, depending on the desired delivery rate, the type of disorder to be treated, the area to be treated and the medication being administered it is possible to custom design the film by selecting and blending various polymers. The final film product may also be fabricated into flexible tapes of varied thickness and width, "spots" of different sizes and shapes or other pre-shaped forms.

The medicaments and pharmaceutical agents set forth in the prior art discussed above may generally be delivered by the drug delivery system of the present invention. Usable medicaments are those which are capable of withstanding the heats and pressures generated in the extrusion process involved in making the film of the present invention. Preferred medicaments include:

Anesthetics/Analgesics-benzocaine, dyclonine HCl, phenol, aspirin, phenacetin, acetaminophen, potassium nitrate, etc.

Anticaries Agents-sodium fluoride, sodium monofluorophosphate, stannous fluoride, etc.

Anti-inflammatories-hydrocortisone acetate, triamcinolone acetonide, dipotassium, glycyrrhizinate, etc.

Antihistamines-chlorpheniramine maleate, ephedrine HCL, diphenhydramine HCL, etc.

Antibiotics-i.e., tetracycline, doxycycline hyclate, meclocycline, minocycline, etc.

Antibacterials-chlorhexidine, cetyl pyridinium chloride, benzethonium chloride, dequalinium chloride, silver sulfadiazene, phenol, thymol, hexedine, hexetidine, alexidine, etc.

Fungistats-nystatin, miconazole, ketoconazole, etc.

The above are illustrative examples of therapeutic agents that are used to treat oral disorders. The present invention is not to be limited to these specific materials especially where it is intended to deliver drug outside of the oral cavity e.g. to skin where other drugs may be desirable.

The film of the present invention has the advantage of being an extruded film, rather than a cast film. When a multi-layered film is involved, the different layers can be coextruded and then laminated together, or else each layer can be separately extruded one on the other, and then laminated together, so that the final multi-layered film is still very thin. The films of the present invention can be made in thicknesses of only 1-10 mils or 0.025-0.25 mm. The films are so thin that when placed in the mouth after they become wet they soon become unobtrusive, and hardly noticeable by most patients.

The film must always have a bioadhesive layer, which enables it to adhere to wet mucosal surfaces. The bioadhesive layer has .[.40-95.Iadd.20-93.Iaddend.% of hydroxypropyl cellulose, 5-60% of a homopolymer of ethylene oxide and 2-10% of a glycol plasticizer (all percents are % by weight).

The Hydroxypropyl cellulose (HPC), useful for purposes of the present invention is commercially available from Hercules, Inc. (Wilmington, DE) under the tradename KLUCEL*. Preferred grades include Klucel MF, with a molecular weight around 600,000 and having a viscosity of 4,000-6,000 cps (Brookfield) in 2 percent water solutions, or Klucel HF, having a molecular weight around 1,000,000 and viscosity of 1500-2500 cps in 1 percent water solution. In general, any HPC having a Molecular Weight above about 100,000 is useful for purposes of this invention.

The homopolymer of ethylene oxide useful for purposes of the present invention has a relatively high molecular weight, i.e., above 100,000 and preferably above 3,000,000. Such polymers are commercially available from various sources. The Union Carbide Corporation material, "Polyox WSR-301", which has a molecular weight of approximately 4,000,000-5,000,000 is most preferred for purposes of the present invention.

The "plasticizer" useful for purposes of the present invention are selected from glycols such as propylene glycol and polyethylene glycol; polyhydric alcohols such as glycerin and sorbitol; glycerol esters such as glycerol triacetate; fatty acid triglycerides such as NEOBEE* M-5 and MYVEROLS*; mineral oil; vegetable oils such as castor oil, etc.

For the uses for the present invention contemplated here, the plasticizer should be non-toxic. The purpose of the plasticizer is to improve polymer melt processing by reducing the polymer melt viscosity and to impart flexibility to the final product.

The preferred plasticizer for use in the present invention is either propylene glycol or polyethylene glycol (such as is available from Union Carbide Corporation as their series of Carbowaxes which runs from 200 to 600 molecular weight, of which we prefer to use Carbowax 400, which has a molecular weight of 400, average.

In addition to the polymers and plasticizer which are required ingredients of the films of the present invention, minor amounts of other non-essential but customary ingredients will often be used if desired, e.g., antioxidants, preservatives, flavors, colorants.

DETAILED DESCRIPTION

The following examples will serve to illustrate the present invention in greater detail. The units shown in the examples are parts by weight. The thickness of the layers is expressed in either mils (0.001 inches) or millimeters. For easy conversion, 4 mils is approximately equal to 0.1 mm.

EXAMPLE 1

Triple Layered Laminate Containing Sodium Fluoride for Anticaries Protection

This three layered film laminate is comprised of a "bioadhesive" layer, a sodium fluoride "reservoir" layer and, an "outer protective barrier membrane" layer, in which the composition and thickness of each layer are as shown below:

______________________________________                              Outer                              Protective           Bio-     % w/w     Barrier           adhesive Reservoir Membrane           Layer    Layer     Layer           (4 mils) (1 mil)   (1 mil)Ingredients     (0.1 mm) (0.025 mm)                              (0.025 mm)______________________________________Polyethylene oxide           60.0     --        --homopolymer (UnisonCarbide-Polyox* WSR-301)Hydroxypropyl Cellulose           30.0     20.0      24.0(Hercules, Inc.-Klucel* MF)Polyethylene (Allied           5.0      --        --Chemical-6A)(Low Density)Propylene Glycol, U.S.P.           3.0      --        --Polyethylene Glycol           2.0      --        --400 (Union Carbide)Ethyl Cellulose (Hercules,           --       59.0      69.6Inc.-N100F)Caprylic/Capric --        5.0      6.0Triglyceride(PVOIncorporated-Neobee M-5)Sodium Fluoride, U.S.P.           --       16.0      0.4           100.0    100.0     100.0______________________________________

The process used to make the above laminate was:

a. Powder Blending-Each layer is made separately and all ingredients used therein except propylene glycol and Neobee M-5 (liquid plasticizers) are placed in a Patterson Kelley (PK) V-blender equipped with liquid addition capabilities. The ingredients which are all powders are blended for approximately 10-15 minutes while the liquid plasticizer is slowly added to the mix. Three separate powder blends are made, one for each layer.

b. Extrusion Process-A standard Johnson 2-1/2 inch vinyl/polyolefin extruder equipped with a single three stage screw was used to extrude the "powder blend". The temperature conditions for the water soluble powders are however quite different from those used for vinyls and polyolefins. The temperature (°C.) profile for the "reservoir" and "membrane layers" of the triple laminate was as follows:

______________________________________  Barrel Zone 1            100  Barrel Zone 2            125  Barrel Zone 3            135  Barrel Zone 4            145  Barrel Zone 5            160  Barrel Zone 6            170  Adapter   180  Die Zone 1            180  Die Zone 2            180  Die Zone 3            180______________________________________

The films which had a width of 18 inches, were extruded at approximately 20 feet/minute through a flat lipped die. The temperature profile for the "bioadhesive layer" was:

______________________________________  Barrel Zone 1            125  Barrel Zone 2            140  Barrel Zone 3            165  Barrel Zone 4            170  Barrel Zone 5            185  Barrel Zone 6            185  Adapter   185  Die Zone 1            185  Die Zone 2            185  Die Zone 3            185______________________________________

Each layer is extruded separately with the first layer extruded as a "free film". Successive layers are extruded onto each other and laminated by passing them through heated stainless steel rollers.

Test Results:

In vitro fluoride ion release studies were conducted on samples of the above described triple laminate film measuring 0.5 cm×1.25 cm (0.625 cm2) according to the following procedures:

The test sample is adhered to a glass slide by prewetting the film and placing the bioadhesive layer on the glass surface. The slide is then immersed in a beaker containing 100 ml of distilled water with continuous stirring. Five milliliter aliquots are withdrawn from the solution, at prescribed time intervals, and analyzed for fluoride content with an Orion Ionanalyzer equipped with a fluoride specific electrode. Release rates are then calculated from the data.

The results obtained indicated fluoride release rates in the order of 0.05-0.2 mgs/cm2 /hr for 24 hours. This falls within the desired range for maintaining constant low levels of fluoride in the mouth and enhanced anticaries activity. Release rates may be tailored to desired use levels by modification of the film composition and construction.

EXAMPLE 2

Single Layer Adhesive Film Containing Hydrocortisone Acetate (0.5%) As An Anti-Inflammatory Agent

The composition of the film, which was 0.1 mm. thick, was as follows:

______________________________________Ingredients           % w/w______________________________________Ethylene Oxide Homopolymer                 59.4(Polyox* WSR-301)Hydroxypropyl Cellulose                 30.0(Klucel* MF)Polyethylene (AC-6A)  5.0Propylene Glycol      3.0Polyethylene Glycol 400                 2.0Butylated Hydroxy Toluene (BHT)                 0.1FCC (preservative)Hydrocortisone Acetate                 0.5                 100.0______________________________________

The powder blending process and extruder conditions used were the same as those described in Example I for the "bioadhesive layer" of the sodium fluoride trilaminate. In vitro tests were performed on the above film and demonstrated a prolonged drug release pattern.

EXAMPLE 3

Single Layer Adhesive Film Containing Triamcinolone Acetonide (0.1%) As An Anti-Inflammatory

The composition of the film, which was 0.1 mm. thick, was as follows:

______________________________________Ingredients          % w/w______________________________________Ethylene Oxide Homopolymer                59.9(Polyox WSR-301)Hydroxypropyl Cellulose                29.9(Klucel MF)Polyethylene (AC-6A) 5.0Propylene Glycol     3.0Polyethylene Glycol 400                2.0BHT                  0.1Triamcinolone Acetonide                0.1                100.0______________________________________

The powder blending process and extruder conditions used to make the film of this Example 3 were the same as those of the "bioadhesive layer" of Example I.

Other desired active medicament ingredients may be incorporated into the adhesive films of any of Examples 1-3 in place of the particular medicament used in said examples. These include Benzocaine (analgesic), Potassium nitrate (analgesic), Silver sulfadiazene (antimicrobial),

Chlorhexidine (antimicrobial), miconazole nitrate (antifungal), Benzethonium chloride (antimicrobial), Tetracycline (antibiotic) and other similar therapeutic compounds.

EXAMPLE 4

Analgesic Films with Potassium Nitrate

This example shows 5 variations of the film having different solubilities, resulting in different release rates.

______________________________________         % w/wIngredients     1      2       3    4     5______________________________________Polyethylene oxide           23.75  57.00   55.00                               55.00 57.00homopolymer (Polyox*WSR-301)Hydroxypropyl Cell-           68.30  --      --   --    --ulose, N.F. (Klucel* HF)Hydroxypropyl Cell-           --     28.40   29.90                               22.40 22.40ulose, N.F. (Klucel* MF)Ethyl Cellulose --     4.75    5.00 12.50 12.50Polyethylene Glycol 400           1.90   1.90    2.00 2.00  2.00Polyethylene Glycol 8000           0.95   --      --   --    --Propylene Glycol, U.S.P.           --     2.85    3.00 3.00  3.00BHT, F.C.C.     0.10   0.10    0.10 0.10  0.10Potassium Nitrate, F.C.C.           5.00   5.00    5.00 5.00  3.00______________________________________

The above ingredients are blended in a Patterson-Kelly powder blender equipped with liquid addition capabilities. The resulting powder blend is then extruded into film on a Killion or Johnson vinyl extruder using processing procedures similar to those of the bioadhesive layer of Example I.

example 5

Anesthetic Films with Benzocaine (Laminate)

This is an example of a two-layer laminate. The processing conditions used were similar to those of the bioadhesive layer and outer protective barrier membrane layer of Example I.

______________________________________A.      Inner medicated bioadhesive layer   Polyoxyethylene Homopolymer                        57.00   (Polyox* WSR-301)   Hydroxypropyl Cellulose, N.F.                        28.40   (Klucel* MF)   Polyethylene (AC-6A) 4.75   Propylene Glycol, U.S.P.                        2.85   Polyethylene Glycol 400                        1.90   BHT, F.C.C.          0.10   Benzocaine, U.S.P.   5.00                        100.00B.      Outer protective/barrier layer   Hydroxypropyl Cellulose                        78.00   (Klucel* MF)   Ethyl Cellulose      20.00   Polyethylene Glycol 400                        2.00                        100.00______________________________________

Part A was extruded on a Johnson extruder followed by subsequent extrusion and lamination of Part B to A.

Samples were applied to oral lesions, and provided profound anesthetic effects (lasting several hours) within minutes of application.

The identical two-layer laminate may also be made by coextruding the inner medicated bioadhesive layer (Part A) and the outer protective barrier layer (Part B) through separate die slots within a coextruder and laminating the two layers together.

EXAMPLE 6

Anesthetic Films with Phenol and Dyclonine HCl

Four variations of a single layer bioadhesive film were made as shown below:

______________________________________Ingredients      1      2        3    4______________________________________Polyethylene oxide homo-            59.10  54.00    59.70                                 58.20polymer (Polyox* WSR-301)Hydroxypropyl Cellulose            29.45  26.91    29.75                                 29.00(Klucel HF)Ethyl Cellulose  4.93   4.50     4.98 4.85Propylene Glycol, U.S.P.            2.96   2.70     2.99 2.91Polyethylene Glycol 400            1.97   1.80     1.99 1.94BHT, F.C.C.      0.09   0.09     0.09 0.10Phenol, U.S.P.   1.50   --       --   --Dyclonine HCl    --     10.00    0.50 3.00______________________________________

Following the procedures for the bioadhesive layer of Example I, the powders were blended in P-K blender equipped with liquid addition capabilities. Resulting powders were extruded on a Killion laboratory-sized extruder.

EXAMPLE 7

Silver Sulfadiazene Films-Antimicrobial

Three different single-layered bioadhesive films containing 1.0% 0.5% and 0.5% respectively of silver sulfadiazene (SSD) were prepared on a heated Carver laboratory press (designed to simulate extruded conditions) as shown below.

______________________________________              % w/wIngredients          A       B______________________________________Polyethylene oxide homopolymer                60.00   60.00(Polyox* WSR-301)Hydroxypropyl Cellulose                28.9    29.4(Klucel* HF)Polyethylene (AC-6A) 5.0     5.0Propylene Glycol, U.S.P.                3.0     3.0Polyethylene Glycol 400                2.0     2.0BHT, F.C.C.          0.1     0.1Silver Sulfadiazine  1.0     0.5                100.0   100.0______________________________________

Effects on wound repair and activity against Staphylococcus aureus were evaluated in the guinea pig model. Full-thickness excisions were inoculated with 3.8×105 organisms, (Staph. aureus) and wound surface microbiology samples taken 10 minutes and 24 hours after treatment. Test films were placed on the wound and covered with BIOCLUSIVE* Transparent Dressings secured with elastic tape. Wound contraction was measured over an eight-day period using OPTOMAX* Computer-Assisted Image Analysis. The three films tested were the following:

A. 1.0% Silver Sulfadiazene, 125° C./2 minutes/4 tons

B. 0.5% Silver Sulfadiazene, 125° C./2 minutes/4 tons

C. 0.5% Silver Sulfadiazene, 150° C./3 minutes/4 tons

SILVADENE Cream and an untreated occluded control. The results indicated that:

1. SILVADENE* treated wounds significantly inhibited full-thickness wound contraction.

2. Film A, B and C inhibited wound contraction relative to that of BIOCLUSIVE* dressed wounds.

3. The three SSD films each permitted substantially faster wound contraction than that of wounds treated daily with SILVADENE* cream.

4. All films were very active against S. Aureus 24 hours after inoculation.

The films may be scaled up by using an extruder. This example demonstrates the feasibility of such a film to perform its intended purpose. Use of a press for larger samples would result in a non-uniform and lower-quality film than an extruded film.

Based on the above findings, the films were very effective antibacterial agents, while mildly inhibiting wound contraction. They offer clinicians a convenient and more effective delivery system for antimicrobials which can be place in wounds beneath any dressing or can be laminated to any acceptable dressing face.

Цитування патентів
Цитований патент Дата реєстрації заявки Дата публікації Заявник Назва
US4292299 *7 лип. 198029 вер. 1981Teijin LimitedSlow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4421738 *18 бер. 198220 груд. 1983Eisai Co., Ltd.Sugar-coated tablet containing fat-soluble pharmaceutical material
US4517173 *25 вер. 198114 трав. 1985Nippon Soda Co. Ltd.Mucous membrane-adhering film preparation and process for its preparation
Посилання з інших патентів
Патент, який цитує Дата реєстрації заявки Дата публікації Заявник Назва
US4997830 *7 лют. 19905 бер. 1991The Research Foundation Of State University Of New YorkPharmaceutical composition for the treatment of periodontitis
US5064650 *4 квіт. 198912 лис. 1991Southwest Research InstituteControlled-release salt sensitive capsule for oral use and adhesive system
US5112620 *20 вер. 199012 трав. 1992Mikkur, Inc.Polyethylene glycol ointment for apthous ulcers
US5114718 *20 вер. 199019 трав. 1992The Procter & Gamble CompanySustained release compositions for treating periodontol disease
US5133971 *2 жов. 199028 лип. 1992Phoebe CopelanPersonal dental hygiene assembly
US5135752 *14 жов. 19884 сер. 1992Zetachron, Inc.Buccal dosage form
US5155144 *29 жов. 199013 жов. 1992Manganaro James LPolysaccharide-based porous sheets
US5262164 *17 лис. 198916 лис. 1993The Procter & Gamble CompanySustained release compositions for treating periodontal disease
US5288532 *27 жов. 199222 лют. 1994Viskase CorporationTransferable modifier-containing film
US5364634 *8 лис. 199115 лис. 1994Southwest Research InstituteControlled-release PH sensitive capsule and adhesive system and method
US5374457 *1 жов. 199320 груд. 1994Viskase CorporationTransferable modifier-containing film
US5382391 *23 вер. 199317 січ. 1995Viskase CorporationMethod for producing transferable modifier-containing film
US5447725 *11 чер. 19935 вер. 1995The Procter & Gamble CompanyMethods for aiding periodontal tissue regeneration
US5700478 *19 сер. 199423 груд. 1997Cygnus, Inc.Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5714165 *1 квіт. 19923 лют. 1998Mikkur, Inc.Bioadhesive polyethylene glycol ointment for medicaments
US5851551 *21 чер. 199422 груд. 1998The Gillette CompanySustained-release matrices for dental application
US5894017 *6 чер. 199713 квіт. 1999The Procter & Gamble CompanyDelivery system for an oral care substance using a strip of material having low flexural stiffness
US5906814 *22 жов. 199625 трав. 1999The Andrew Jergens CompanyTopical film-forming compositions
US5906834 *9 жов. 199625 трав. 1999The Gillette CompanyColor changing matrix as wear indicator
US595845210 квіт. 199728 вер. 1999Euro-Celtique, S.A.Extruded orally administrable opioid formulations
US59651614 лис. 199412 жов. 1999Euro-Celtique, S.A.Extruded multi-particulates
US599843116 квіт. 19987 груд. 1999Gillette Canada Inc.Sustained-release matrices for dental application
US60688553 лис. 199530 трав. 2000Euro-Celtique S. A.Pharmaceutical composition containing a fusible carrier and method for producing the same
US62319576 трав. 199915 трав. 2001Horst G. ZerbeRapidly disintegrating flavor wafer for flavor enrichment
US626159923 лип. 199917 лип. 2001Euro-Celtique, S.A.Melt-extruded orally administrable opioid formulations
US633503322 лип. 19991 січ. 2002Euro-Celtique, S.A.Melt-extrusion multiparticulates
US637596315 чер. 200023 квіт. 2002Michael A. RepkaBioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6419906 *12 бер. 200116 лип. 2002Colgate Palmolive CompanyStrip for whitening tooth surfaces
US6503486 *22 лют. 20027 січ. 2003Colgate Palmolive CompanyStrip for whitening tooth surfaces
US6514483 *22 лют. 20024 лют. 2003Colgate Palmolive CompanyStrip for whitening tooth surfaces
US655157929 трав. 200122 квіт. 2003The Procter & Gamble CompanyDelivery systems for a tooth whitener
US656236328 вер. 199813 трав. 2003Noven Pharmaceuticals, Inc.Bioadhesive compositions and methods for topical administration of active agents
US6566350 *21 трав. 200120 трав. 2003Showa Yakuhin Kako Co., Ltd.Minocycline-containing compositions
US658270828 чер. 200024 чер. 2003The Procter & Gamble CompanyTooth whitening substance
US663888122 груд. 200028 жов. 2003Combe IncorporatedDental adhesive device and method of producing same
US666029219 чер. 20019 груд. 2003Hf Flavoring Technology LlpRapidly disintegrating flavored film for precooked foods
US668272113 лют. 200127 січ. 2004Lg Household & Healthcare Ltd.Patches for teeth whitening
US668934413 вер. 200210 лют. 2004Lg Household & Healthcare Ltd.Patches for teeth whitening
US67062812 січ. 200216 бер. 2004Euro-Celtique, S.A.Melt-extrusion multiparticulates
US67434426 лют. 20011 чер. 2004Euro-Celtique, S.A.Melt-extruded orally administrable opioid formulations
US678040127 трав. 200324 сер. 2004Lg Household & Healthcare Ltd.Patches for teeth whitening
US686073619 лют. 20041 бер. 2005Ultradent Products, Inc.Oral treatment devices that include a thin, flexible barrier layer and an endoskeleton treatment or adhesive composition
US688442617 груд. 200226 квіт. 2005The Procter & Gamble Co.Methods for whitening teeth
US694614220 чер. 200220 вер. 2005Lg Household & Healthcare Ltd.Multi-layer patches for teeth whitening
US694924023 трав. 200227 вер. 2005The Procter & Gamble CompanyTooth whitening products
US69645714 лис. 200315 лис. 2005Ultradent Products, Inc.Pre-shaped dental trays and treatment devices and methods that utilize such dental trays
US698187419 лют. 20043 січ. 2006Ultradent Products, Inc.Dental bleaching compositions and devices having a solid activation adhesive layer or region and bleaching gel layer or region
US69977085 груд. 200314 лют. 2006Ultradent Products, Inc.Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto
US700475624 січ. 200328 лют. 2006Ultradent Products, Inc.Pre-shaped dental trays and treatment devices and methods that utilize such dental trays
US701152322 жов. 200314 бер. 2006Ultradent Products, Inc.Bleaching compositions and devices having a solid adhesive layer and bleaching gel adjacent thereto
US701862224 жов. 200228 бер. 2006The Procter & Gamble CompanyStructures and compositions increasing the stability of peroxide actives
US704089723 трав. 20039 трав. 2006Ultradent Products, Inc.Thin, flexible membrane dental trays and systems and methods utilizing such trays
US704854327 трав. 200323 трав. 2006Ultradent Products, Inc.Substantially solid bleaching composition in a tray-like configuration
US705227522 сер. 200330 трав. 2006Ultradent Products, Inc.Kits and methods for bleaching and desensitizing teeth
US705611822 сер. 20036 чер. 2006Ultradent Products, Inc.Compositions and devices having a tray-like configuration for delivering a medicament and methods of manufacturing and using such compositions and devices
US70598578 сер. 200313 чер. 2006Ultradent Products, Inc.Substantially solid desensitizing compositions and devices having a tray-like configuration and methods of manufacturing and using such compositions and devices
US705985819 лют. 200413 чер. 2006Ultradent Products, Inc.Universal tray design having anatomical features to enhance fit
US707404227 трав. 200311 лип. 2006Ultradent Products, Inc.Tray-like dental bleaching devices having a barrier layer and a substantially solid bleaching composition
US71221996 квіт. 200517 жов. 2006The Procter & Gamble CompanyMethods for whitening teeth
US713211316 квіт. 20027 лис. 2006Intelgenx Corp.Flavored film
US719228019 лют. 200420 бер. 2007Ultradent Products, Inc.Dental bleaching devices having a protective adhesive region
US724702231 січ. 200524 лип. 2007Ultradent Products, Inc.Dental tray system with releasable hold inner and outer dental trays
US72644715 трав. 20044 вер. 2007Ultradent Products, Inc.Methods and kits for bleaching teeth while protecting adjacent gingival tissue
US733866415 вер. 20034 бер. 2008The Gillette CompanyColor changing matrix as wear indicator
US735789130 січ. 200415 квіт. 2008Monosol Rx, LlcProcess for making an ingestible film
US742529214 лют. 200216 вер. 2008Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US74522092 трав. 200518 лис. 2008Ultradent Products, Inc.Exoskeleton support for placement of a dental treatment strip
US747039722 жов. 200430 груд. 2008Adhesives Research, Inc.Disintegratable films for diagnostic devices
US74816539 лют. 200527 січ. 2009Oratech LcPreshaped thin-walled dental trays and methods of manufacturing and using such trays
US751072723 груд. 200331 бер. 2009Purdue Pharma L.P.Melt-extrusion multiparticulates
US75760671 груд. 200418 сер. 2009Isis Pharmaceuticals, Inc.Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorption
US76252109 сер. 20041 груд. 2009Ultradent Products, Inc.Treatment devices for providing oral treatments and kits and methods that utilize such treatment devices
US766633728 трав. 200423 лют. 2010Monosol Rx, LlcPolyethylene oxide-based films and drug delivery systems made therefrom
US772746621 лис. 20081 чер. 2010Adhesives Research, Inc.Disintegratable films for diagnostic devices
US776665830 лис. 20043 сер. 2010Align Technology, Inc.Systems and methods for intra-oral diagnosis
US778557228 трав. 200431 сер. 2010Lg Household And Health Care Ltd.Method and device for teeth whitening using a dry type adhesive
US782458814 квіт. 20082 лис. 2010Monosol Rx, LlcMethod of making self-supporting therapeutic active-containing film
US786280210 сер. 20044 січ. 2011Lg Household & Health Care Ltd.Patches for teeth whitening
US791064114 груд. 200622 бер. 2011Monosol Rx, LlcPH modulated films for delivery of actives
US794750831 жов. 200724 трав. 2011Align Technology, Inc.Systems and methods for intra-oral diagnosis
US797261820 вер. 20075 лип. 2011Monosol Rx, LlcEdible water-soluble film containing a foam reducing flavoring agent
US80072779 сер. 200730 сер. 2011Ultradent Products, Inc.Non-custom dental treatment trays and mouth guards having improved anatomical features
US801715022 квіт. 200813 вер. 2011Monosol Rx, LlcPolyethylene oxide-based films and drug delivery systems made therefrom
US80494268 сер. 20081 лис. 2011Tessera, Inc.Electrostatic fluid accelerator for controlling a fluid flow
US807530931 жов. 200713 груд. 2011Align Technology, Inc.Systems and methods for intra-oral drug delivery
US80758726 лют. 200613 груд. 2011Gruenenthal GmbhAbuse-proofed dosage form
US811438320 лис. 200314 лют. 2012Gruenenthal GmbhAbuse-proofed dosage form
US811438414 лип. 200414 лют. 2012Gruenenthal GmbhProcess for the production of an abuse-proofed solid dosage form
US817315222 бер. 20078 трав. 2012Auxilium Us Holdings, LlcStabilized compositions containing alkaline labile drugs
US819272217 чер. 20085 чер. 2012Grunenthal GmbhAbuse-proof dosage form
US820209129 сер. 200819 чер. 2012Ultradent Products, Inc.Dental treatment trays comprising silicone elastomeric material
US82772155 чер. 20062 жов. 2012Ultradent Products, Inc.Universal non-custom dental tray having anatomical features to enhance fit
US828295415 груд. 20089 жов. 2012Monosol Rx, LlcMethod for manufacturing edible film
US83090609 січ. 201213 лис. 2012Grunenthal GmbhAbuse-proofed dosage form
US832388917 чер. 20084 груд. 2012Gruenenthal GmbhProcess for the production of an abuse-proofed solid dosage form
US838315223 січ. 200926 лют. 2013Gruenenthal GmbhPharmaceutical dosage form
US842005611 жов. 201116 квіт. 2013Grunenthal GmbhAbuse-proofed dosage form
US843967413 груд. 201114 трав. 2013Align Technology, Inc.Systems and methods for intra-oral drug delivery
US844441329 сер. 201121 трав. 2013Ultradent Products, Inc.Non-custom dental treatment trays having improved anatomical features
US846575922 бер. 200718 чер. 2013Auxilium Us Holdings, LlcProcess for the preparation of a hot-melt extruded laminate
US84758327 сер. 20092 лип. 2013Rb Pharmaceuticals LimitedSublingual and buccal film compositions
US855728620 квіт. 200015 жов. 2013Euroceltique, S.A.Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
US860351410 лип. 200710 груд. 2013Monosol Rx, LlcUniform films for rapid dissolve dosage form incorporating taste-masking compositions
US86132859 квіт. 201024 груд. 2013Philip Morris Products S.A.Extrudable and extruded compositions for delivery of bioactive agents, method of making same and method of using same
US8647314 *27 лют. 200911 лют. 2014Lts Lohmann Therapie-Systeme AgGingival wafer
US864760728 квіт. 200611 лют. 2014Lg Household & Health Care Ltd.Patches for teeth whitening
US865237829 бер. 201318 лют. 2014Monosol Rx LlcUniform films for rapid dissolve dosage form incorporating taste-masking compositions
US865244619 лис. 200318 лют. 2014Lg Household & Healthcare Ltd.Apparatus and method for whitening teeth
US866368713 трав. 20104 бер. 2014Monosol Rx, LlcFilm compositions for delivery of actives
US866369617 сер. 20124 бер. 2014Monosol Rx, LlcFilm delivery system for tetrahydrolipstatin
US868543726 бер. 20091 квіт. 2014Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US872133215 січ. 201313 трав. 2014Ultradent Products, Inc.Non-custom dental treatment trays having improved anatomical features
US87220867 бер. 200813 трав. 2014Gruenenthal GmbhDosage form with impeded abuse
US87651678 вер. 20061 лип. 2014Monosol Rx, LlcUniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US881528923 трав. 201326 сер. 2014Purdue Pharma L.P.Tamper resistant dosage forms
US882192923 трав. 20132 вер. 2014Purdue Pharma L.P.Tamper resistant dosage forms
US883492523 трав. 201316 вер. 2014Purdue Pharma L.P.Tamper resistant dosage forms
US884608623 трав. 201330 вер. 2014Purdue Pharma L.P.Tamper resistant dosage forms
US88831873 трав. 201211 лис. 2014Auxilium Us Holdings, LlcStabilized compositions containing alkaline labile drugs
US889498724 сер. 200725 лис. 2014William H. McKennaTamper resistant dosage forms
US889498823 трав. 201325 лис. 2014Purdue Pharma L.P.Tamper resistant dosage forms
US890049723 сер. 20132 груд. 2014Monosol Rx, LlcProcess for making a film having a substantially uniform distribution of components
US890049823 сер. 20132 груд. 2014Monosol Rx, LlcProcess for manufacturing a resulting multi-layer pharmaceutical film
US890627723 сер. 20139 груд. 2014Monosol Rx, LlcProcess for manufacturing a resulting pharmaceutical film
US891171923 трав. 201316 груд. 2014Purdue Pharma LpTamper resistant dosage forms
US894481921 груд. 20103 лют. 2015Ranir, LlcDevice and method for delivering an oral care agent
US89561602 лип. 200217 лют. 2015Ranir, LlcDevice and method for delivering an oral care agent
US897482610 чер. 201110 бер. 2015Monosol Rx, LlcNanoparticle film delivery systems
US908481616 жов. 201421 лип. 2015Purdue Pharma L.P.Tamper resistant dosage forms
US909561416 жов. 20144 сер. 2015Purdue Pharma L.P.Tamper resistant dosage forms
US909561516 жов. 20144 сер. 2015Purdue Pharma L.P.Tamper resistant dosage forms
US910166116 жов. 201411 сер. 2015Purdue Pharma L.P.Tamper resistant dosage forms
US910834023 сер. 201318 сер. 2015Monosol Rx, LlcProcess for manufacturing a resulting multi-layer pharmaceutical film
US91619171 лис. 201020 жов. 2015Grünenthal GmbHProcess for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9198865 *17 лис. 20061 груд. 2015Dow Global Technologies LlcBiologically active composition comprising ethylcellulose
US936444517 жов. 201414 чер. 2016Auxilium Us Holdings, LlcStabilized compositions containing alkaline labile drugs
US94864123 чер. 20158 лис. 2016Purdue Pharma L.P.Tamper resistant dosage forms
US94864133 чер. 20158 лис. 2016Purdue Pharma L.P.Tamper resistant dosage forms
US94923893 чер. 201515 лис. 2016Purdue Pharma L.P.Tamper resistant dosage forms
US94923903 чер. 201515 лис. 2016Purdue Pharma L.P.Tamper resistant dosage forms
US94923913 чер. 201515 лис. 2016Purdue Pharma L.P.Tamper resistant dosage forms
US94923923 чер. 201515 лис. 2016Purdue Pharma L.P.Tamper resistant dosage forms
US94923933 чер. 201515 лис. 2016Purdue Pharma L.P.Tamper resistant dosage forms
US949841021 груд. 200722 лис. 2016Colgate-Palmolive CompanyOral and personal care compositions and methods
US95453803 чер. 201517 січ. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US955497630 лип. 201331 січ. 2017The Procter & Gamble CompanyTooth whitening product
US95792851 лют. 201128 лют. 2017Gruenenthal GmbhPreparation of a powdery pharmaceutical composition by means of an extruder
US958596110 груд. 20127 бер. 2017Adhesives Research, Inc.Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents
US962980719 квіт. 201625 квіт. 2017Grünenthal GmbHAbuse-proofed dosage form
US96363031 вер. 20112 трав. 2017Gruenenthal GmbhTamper resistant dosage form comprising an anionic polymer
US964285015 лис. 20169 трав. 2017Purdue Pharma L.P.Method of providing sustained analgesia with buprenorphine
US965585327 трав. 201623 трав. 2017Grünenthal GmbHTamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US967561024 сер. 201613 чер. 2017Grünenthal GmbHAbuse-proofed dosage form
US96874546 січ. 201627 чер. 2017Indivior Uk LimitedSublingual and buccal film compositions
US97175777 жов. 20161 сер. 2017Ultradent Products, Inc.Non-custom dental tray having anatomical cuspid-bicuspid cuts and/or V or U-shaped indentation in bottom wall
US971768223 січ. 20131 сер. 2017Intelgenx CorporationSolid oral film dosage forms and methods for making same
US973749027 трав. 201422 сер. 2017Grünenthal GmbHTamper resistant dosage form with bimodal release profile
US975070111 груд. 20155 вер. 2017Grünenthal GmbHPharmaceutical dosage form
US976388624 січ. 201719 вер. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US976393324 січ. 201719 вер. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US977041624 січ. 201726 вер. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US977041724 січ. 201726 вер. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US977580824 січ. 20173 жов. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US977580924 січ. 20173 жов. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US977581024 січ. 20173 жов. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US977581124 січ. 20173 жов. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US977581213 вер. 20163 жов. 2017Purdue Pharma L.P.Tamper resistant dosage forms
US98018378 трав. 200731 жов. 2017The University Of MississippiStabilized formulation of triamcinolone acetonide
US20030053962 *16 квіт. 200220 бер. 2003Zerbe Horst G.Flavored film
US20030059381 *24 жов. 200227 бер. 2003Goodhart Lesle MarieStructures and compositions increasing the stability of peroxide actives
US20030167556 *5 бер. 200211 вер. 2003Consumers Choice Systems, Inc.Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US20040018241 *13 трав. 200329 січ. 2004Noven Pharmaceuticals, Inc.Bioadhesive compositions and methods for topical administration of active agents
US20040120991 *5 вер. 200324 чер. 2004Mars IncorporatedEdible films having distinct regions
US20040146836 *24 січ. 200329 лип. 2004Andersen Scot N.Pre-shaped dental trays and treatment devices and methods that utilize such dental trays
US20040219111 *28 трав. 20044 лис. 2004Ji-Young KimMethod and device for teeth whitening using a dry type adhesive
US20040241294 *31 трав. 20032 груд. 2004Barabolak Roman M.Edible films including aspartame and methods of making same
US20040241615 *27 трав. 20032 груд. 2004Allred Peter M.Tray-like dental bleaching devices having a barrier layer and a substantially solid bleaching composition
US20040241616 *27 трав. 20032 груд. 2004Ultradent Products, Inc.Substantially solid bleaching composition in a tray-like configuration
US20040241617 *8 сер. 20032 груд. 2004Allred Peter M.Substantially solid desensitizing compositions and devices having a tray-like configuration and methods of manufacturing and using such compositions and devices
US20040258896 *30 січ. 200423 груд. 2004Monosolrx Llc.Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20050037055 *28 трав. 200417 лют. 2005Monosolrx Llc.Polyethylene oxide-based films and drug delivery systems made therefrom
US20050089568 *16 вер. 200328 квіт. 2005Euro-Celtique S.A.Melt-extruded orally administrable opioid formulations
US20050089820 *5 груд. 200328 квіт. 2005Allred Peter M.Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto
US20050100515 *8 вер. 200412 трав. 2005The Procter & Gamble CompanyTooth whitening products
US20050136381 *9 лют. 200523 чер. 2005Andersen Scot N.Preshaped thin-walled dental trays and methods of manufacturing and using such trays
US20050143303 *18 лис. 200430 чер. 2005Nastech Pharmaceutical Company Inc.Intranasal administration of glucose-regulating peptides
US20050186150 *19 лют. 200425 сер. 2005Allred Peter M.Dental bleaching devices having a protective adhesive region
US20050186539 *19 лют. 200425 сер. 2005Mclean Bruce S.Universal tray design having anatomical features to enhance fit
US20050196443 *1 груд. 20048 вер. 2005Isis Pharmaceuticals, Inc.Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20050208108 *19 бер. 200422 вер. 2005Jannusch Leonard CThermoplastic films and methods for making
US20060057165 *9 вер. 200516 бер. 2006Dimitrios DimitrakoudisClostridium botulinum toxin formulation and method for reducing weight
US20060074025 *2 груд. 20056 квіт. 2006Nastech Pharmaceutical Company Inc.Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20060115782 *30 лис. 20041 чер. 2006Chunhua LiSystems and methods for coating a dental appliance
US20060115785 *30 лис. 20041 чер. 2006Chunhua LiSystems and methods for intra-oral drug delivery
US20060116561 *30 лис. 20041 чер. 2006Tricca Robert ESystems and methods for intra-oral diagnosis
US20060171905 *31 січ. 20053 сер. 2006Allred Peter MDental bleaching compositions having a protective coating applied thereto
US20060172260 *31 січ. 20053 сер. 2006Allred Peter MDental tray system with releasable hold inner and outer dental trays
US20060193794 *28 квіт. 200631 сер. 2006Ji-Young KimPatches for teeth whitening
US20060207721 *17 бер. 200521 вер. 2006Greg SlominskiPolymer adhesive splicing of water-soluble, orally ingestible thin film webs
US20070172515 *19 січ. 200726 лип. 2007Monosolrx, LlcFilm bandage for mucosal administration of actives
US20070269388 *31 лип. 200722 лис. 2007The Procter & Gamble CompanyTooth whitening strips
US20070269491 *31 лип. 200722 лис. 2007The Procter & Gamble CompanyTooth whitening strips
US20070269520 *31 лип. 200722 лис. 2007The Procter & Gamble CompanyTooth whitening strips
US20070275023 *31 лип. 200729 лис. 2007The Procter & Gamble CompanyTooth whitening strips
US20070298087 *18 січ. 200727 груд. 2007Biegajski James ETwo-phase mucoadhesive composition
US20070298380 *26 чер. 200627 груд. 2007Ultradent Products, Inc.Dental treatment devices adapted for improved lingual side adhesion
US20080038211 *31 лип. 200714 лют. 2008Sagel Paul ATooth whitening strips
US20080075825 *20 вер. 200727 бер. 2008Fuisz Richard CEdible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
US20080119698 *31 жов. 200722 трав. 2008Tricca Robert ESystems and methods for intra-oral diagnosis
US20080200452 *20 лип. 200621 сер. 2008Petra ObermeierOral, Rapidly Disintegrating Film, Which Cannot be Spat Out, for a Neuroleptic
US20080226695 *29 трав. 200818 вер. 2008Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20080234200 *20 трав. 200825 вер. 2008Nastech Pharmaceutical Company Inc.Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080260805 *14 квіт. 200823 жов. 2008Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20080268027 *11 лип. 200830 жов. 2008Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20080292683 *24 трав. 200727 лис. 2008Monosolrx, Llc.Film shreds and delivery system incorporating same
US20080299005 *22 жов. 20044 груд. 2008Meathrel William GDisintegratable films for diagnostic devices
US20080318837 *1 груд. 200625 груд. 2008Nastech Pharmaceutical Company Inc.Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20080318861 *7 груд. 200625 груд. 2008Nastech Pharmaceutical Company Inc.Mucosal Delivery of Stabilized Formulations of Exendin
US20090087812 *2 жов. 20072 квіт. 2009Ultradent Products, Inc.Self-customizable dental treatment trays
US20090095313 *16 трав. 200816 квіт. 2009Fuisz Richard CSmokeless Tobacco Product, Smokeless Tobacco Product in the Form of a Sheet, Extrudable Tobacco Composition, Method for Manufacturing a Smokeless Tobacco Product, Method for Delivering Super Bioavailable Nicotine Contained in Tobacco to a User, and Packaged Smokeless Tobacco Product Sheet
US20090098192 *10 жов. 200816 квіт. 2009Fuisz Richard CExtrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
US20090130058 *17 лис. 200621 трав. 2009Hall Mark JBiologically active composition comprising ethylcellulose
US20090136555 *22 бер. 200728 трав. 2009Crowley Michael MProcess for the preparation of a hot-melt extruded laminate
US20090264385 *22 бер. 200722 жов. 2009Crowley Michael MStabilized compositions containing alkaline labile drugs
US20100028829 *31 лип. 20084 лют. 2010Ultradent Products, Inc.Chemically activated dental bleaching trays
US20100040727 *18 сер. 200818 лют. 2010Monosol Rx, LlcMethod for Improving Uniformity of Content in Edible Film Manufacturing
US20100150987 *15 груд. 200817 чер. 2010Monosol Rx, LlcMethod for Manufacturing Edible Film
US20100221309 *13 трав. 20102 вер. 2010Monosol Rx, LlcFilm compositions for delivery of actives
US20100285130 *30 квіт. 201011 лис. 2010Monosol Rx, LlcCoating of complexed actives in film formulations
US20100297232 *19 трав. 200925 лис. 2010Monosol Rx, LlcOndansetron film compositions
US20110009834 *27 лют. 200913 січ. 2011Lts Lohmann Therapie-Systeme AgGingival wafer
US20110086329 *21 груд. 201014 квіт. 2011Ranir/Dcp CorporationDevice and method for delivering an oral care agent
US20110142942 *10 груд. 201016 чер. 2011Monosol Rx, LlcUSE OF pH SENSITIVE COMPOUNDS IN TASTE MASKING OF DRUG SUBSTANCES WITHIN ORAL THIN FILM STRIPS
US20110160264 *27 груд. 201030 чер. 2011Monosol Rx, LlcOrally administrable film dosage forms containing ondansetron
US20110178048 *8 трав. 200721 лип. 2011Repka Michael AStabilized formulation of triamcinolone acetonide
US20110182969 *21 бер. 201128 лип. 2011Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20110200715 *28 квіт. 201118 сер. 2011Monosol Rx, LlcMulti-layer films having uniform content
CN101489756B22 бер. 20077 сер. 2013奥克思利尤姆国际控股公司Process for the preparation of a hot-melt extruded laminate
EP0598606A1 *17 лис. 199325 трав. 1994JOHNSON & JOHNSON CONSUMER PRODUCTS, INC.Extrudable compositions for topical or transdermal drug delivery
EP1659976A2 *7 трав. 200431 трав. 2006Ultradent Products, Inc.Compositons and devices having a tray-like configuration for delivering an oral medicament and methods of manufacturing and using such compositions and devices
EP1659976A4 *7 трав. 20044 бер. 2009Ultradent Products IncCompositons and devices having a tray-like configuration for delivering an oral medicament and methods of manufacturing and using such compositions and devices
EP2010156A2 *22 бер. 20077 січ. 2009Auxilium International Holdings, Inc.Stabilized compositions containing alkaline labile drugs
EP2010156A4 *22 бер. 200718 лип. 2012Auxilium Int Holdings IncStabilized compositions containing alkaline labile drugs
EP3141248A1 *22 бер. 200715 бер. 2017Auxilium International Holdings, Inc.Stabilized compositions containing alkaline labile drugs
WO1992007640A1 *23 вер. 199114 трав. 1992Fmc CorporationPolysaccharide-based porous sheets
WO2007112285A222 бер. 20074 жов. 2007Auxilium Pharmaceuticals, Inc.Process for the preparation of a hot-melt extruded laminate
WO2007112285A3 *22 бер. 20072 жов. 2008Auxilium Pharmaceuticals IncProcess for the preparation of a hot-melt extruded laminate
WO2011081625A130 груд. 20097 лип. 2011Novartis AgMelt extruded thin strips containing coated pharmaceutical actives
WO2011081628A130 груд. 20097 лип. 2011Novartis AgMelt extruded nicotine thin strips
WO2017093941A11 груд. 20168 чер. 2017Niconovum Usa, Inc.Multi-phase delivery compositions and products incorporating such compositions
Класифікації
Класифікація США424/676, 424/449, 424/435
Міжнародна класифікаціяA61K9/00
Об’єднана класифікаціяA61K9/006
Європейська класифікаціяA61K9/00M18D
Юридичні події
ДатаКодДіяОпис
3 чер. 1991FPAYFee payment
Year of fee payment: 4
25 трав. 1995FPAYFee payment
Year of fee payment: 8
3 трав. 1999FPAYFee payment
Year of fee payment: 12